Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2024—OGT has launched the RNA-based SureSeq Myeloid Fusion panel, a next-generation sequencing tool for identifying key fusion genes implicated in acute myeloid leukemia. The panel identifies more than 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. It is fully compatible with OGT’s Universal NGS Complete Workflow Solution and complimentary data analysis software, Interpret.
July 2024—Progentec Diagnostics proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available. The AiSLE DX lupus disease activity index and AiSLE DX lupus flare risk index tests are the result of a collaboration with Mayo Clinic Laboratories and are now accessible to all clients of Mayo Clinic Labs.
July 2024—Haemonetics Corp. has received FDA 510(k) clearance for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. The cartridge extends the TEG 6s’ viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries and procedures and liver transplantation in laboratory and point-of-care settings.
June 2024—Leica Biosystems announced that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the U.S. Food and Drug Administration. The Aperio GT 450 DX is proven technology that offers both SVS and Native DICOM and consistently delivers high-quality images at a turnaround time of less than 32 seconds per slide.
June 2024—Nova Biomedical announced the U.S. launch of its 510(k)-cleared, next-generation StatStrip glucose hospital meter system. New features include a Linux operating system with enhanced cybersecurity, RFID data entry, wireless charging, and a hematocrit range of five to 75 percent. The meter is FDA cleared for testing patients who are critically ill.
June 2024—HemoSonics received special 510(k) clearance from the FDA for the expanded use of arterial blood samples with its Quantra QStat cartridge. The QStat cartridge used with the Quantra hemostasis analyzer first received 510(k) clearance in 2022 for use in venous whole blood samples.
June 2024—The May issue of CAP TODAY printed a press release from Leica Biosystems that departed from the release provided by the company. The most egregious mistake in our item is that we stated the Aperio GT 450 DX is for research use only, which is our sheer error and serious mistake. The CAP TODAY headline and the Leica Biosystems press release make clear that the instrument received FDA 510(k) clearance.
June 2024—Streck announced the launch of its Protein Plus BCT direct draw whole blood collection tube to provide sample integrity during storage, shipping, and handling of blood samples. The tube contains a preservative reagent that minimizes ex vivo hemolysis and platelet activation in collected samples, limits the interference of proteins released from blood cells, and maintains draw-time concentrations of plasma proteins during whole blood storage at ambient temperature. It is compatible with mass spectrometry and immunoassay-based proteomic analysis and is for research use only.
June 2024—QuidelOrtho has added the Ark Fentanyl II assay to its U.S. Vitros XT 7600 and 5600 integrated systems and Vitros 4600 chemistry system. It is offered as a MicroTip Partnership Assay; MPAs are validated for use on MicroTip-capable Vitros systems through a collaboration between contracted vendors and a team of QuidelOrtho scientists and professionals. The assay provides a result in less than 10 minutes.
June 2024—The Clinical and Laboratory Standards Institute has released a new update of “M100: Performance Standards for Antimicrobial Susceptibility Testing” (34th edition) and revised editions of “M02: Performance Standards for Antimicrobial Disk Susceptibility Tests” (14th edition) and “M07: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically” (12th edition). The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using procedures defined in CLSI standards M02, M07, and M11 (“Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria”).
